[{"id":"d7b63745-b754-4312-8d12-7caa21ac459b","acronym":"BGB-A317-3111-10188-101","url":"https://clinicaltrials.gov/study/NCT04282018","created_at":"2021-01-18T20:47:22.139Z","updated_at":"2024-07-02T16:34:37.351Z","phase":"Phase 1/2","brief_title":"Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab","source_id_and_acronym":"NCT04282018 - BGB-A317-3111-10188-101","lead_sponsor":"BeiGene","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Tevimbra (tislelizumab-jsgr) • Brukinsa (zanubrutinib) • BGB-10188"],"overall_status":"Recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 05/25/2020","start_date":" 05/25/2020","primary_txt":" Primary completion: 05/06/2025","primary_completion_date":" 05/06/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-07"}]